Human TRAILR4/TNFRSF10D Antibody

Catalog # Availability Size / Price Qty
MAB633
MAB633-SP
TRAIL R4/TNFRSF10D Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human TRAIL R4/TNFRSF10D Antibody.
2 Images
Product Details
Citations (18)
FAQs
Supplemental Products
Reviews (1)

Human TRAILR4/TNFRSF10D Antibody Summary

Species Reactivity
Human
Specificity
Detects human TRAIL R4/TNFRSF10D in ELISAs and Western blots. In sandwich immunoassays, less than 5% cross-reactivity with recombinant human (rh) TRAIL R1, rhTRAIL R2, TRAIL R3, rhTRAIL, rhTNF‑ alpha, and rhTNF-beta is observed.
Source
Monoclonal Mouse IgG1 Clone # 104918
Purification
Protein A or G purified from ascites
Immunogen
Mouse myeloma cell line NS0-derived recombinant human TRAIL R4/TNFRSF10D
Ala56-His211
Accession # Q9UBN6
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Flow Cytometry
2.5 µg/106 cells
Human whole blood granulocytes
CyTOF-ready
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
 

Human TRAIL R4/TNFRSF10D Sandwich Immunoassay

Recommended Concentration
Reagent
ELISA Capture (Matched Antibody Pair)
2-8 µg/mL 

Use in combination with:

Detection Reagent: Human TRAILR4/TNFRSF10D Biotinylated Antibody (Catalog # BAF633)

Standard: Recombinant Human TRAILR4/TNFRSF10D Fc Chimera Protein, CF (Catalog # 633-TR)

Neutralization
Measured by its ability to neutralize TRAIL R4/TNFRSF10D-mediated inhibition of cytotoxicity in the L‑929 mouse fibroblast cell line. The Neutralization Dose (ND50) is typically 0.3-1.8 µg/mL in the presence of 90 ng/mL Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera, 20 ng/mL of Recombinant Human TRAIL/TNFSF10, and actinomycin D.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization TRAIL R4/TNFRSF10D Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human TRAIL R4/TNFRSF10D Antibody. View Larger

TRAIL R4/TNFRSF10D Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human TRAIL R4/TNFRSF10D Antibody. In the presence of the metabolic inhibitor actinomycin D, Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (Catalog # 633-TR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TEC) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line). Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (20 ng/mL) activity elicited by Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (90 ng/mL) is neutralized (green line) by increasing concentrations of Human TRAIL R4/TNFRSF10D Monoclonal Antibody (Catalog # MAB633). The ND50 is typically 0.3-1.8 µg/mL.

Flow Cytometry Detection of Human TRAILR4/TNFRSF10D/DcR2 by Flow Cytometry View Larger

Detection of Human TRAILR4/TNFRSF10D/DcR2 by Flow Cytometry Flow cytometry studies of scFv-Fc-scTRAIL molecules and Fc-scTRAIL on Colo205 and HCT116 cells(A) Expression levels of EGFR, HER2, HER3, EpCAM, and TRAIL-receptors were investigated after treatment of the cells with medium or 250 ng/ml BZB for 16 h. (B) Serial dilutions of the molecules were analyzed. (C) 20 nM scTRAIL units were analyzed after preincubation of the cells with PBA or a 200-fold molar excess of the respective blocking antibody. Binding of Fc-scTRAIL was measured in the presence of all blocking antibodies separately and is here represented as the mean of blocking with all different antibodies. Bound molecules were detected via anti-FLAG-PE. relative MFI, relative median fluorescence intensity. Pairwise comparisons were performed by unpaired t test (two-tailed; *P < 0.05; **P < 0.01; ***P < 0.001; ns, P > 0.05). Image collected and cropped by CiteAb from the following publication (https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.24379), licensed under a CC-BY license. Not internally tested by R&D Systems.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS.
Loading...
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: TRAILR4/TNFRSF10D

Human TRAIL R4, also called decoy receptor 2 (DcR2) and TRUNND (TRAIL receptor with a truncated death domain), is a type I, TNF R family transmembrane protein, which is a receptor for TRAIL (APO2 ligand). In the TNF superfamily nomenclature, TRAIL R4 is designated as TNFRSF10D. TRAIL R4 is unique among the TRAIL receptors in that its cytoplasmic domain contains a truncated consensus death domain motif. Binding of TRAIL R4 does not result in an apoptotic signal. Overexpression of TRAIL R4 can protect cells bearing TRAIL R1 and/or TRAIL R2 from TRAIL-mediated apoptosis. The human soluble TRAIL R4/Fc chimera neutralizes the ability of TRAIL to induce apoptosis.

References
  1. Griffith, T.S. et al. (1998) Curr. Opin. Immunol. 10:559.
  2. Pan, G. et al. (1998) FEBS lett 424:41.
  3. Marsters, S.A. et al. (1997) Cur. Biol. 7:1003.
  4. Degli-Esposti, M.A. et al. (1997) Immunity 7:813.
Long Name
TRAIL Receptor 4
Entrez Gene IDs
8793 (Human)
Alternate Names
CD264 antigen; CD264; DcR2; DCR2decoy with truncated death domain; Decoy receptor 2; TNF receptor-related receptor for TRAIL; TNF-related apoptosis-inducing ligand receptor 4; TNFRSF10D; TRAIL R4; TRAILR4; TRAIL-R4; TRAILR4TRAIL receptor 4; TRUNDDTRAIL receptor with a truncated death domain; tumor necrosis factor receptor superfamily member 10D; tumor necrosis factor receptor superfamily, member 10d, decoy with truncateddeath domain

Product Datasheets

You must select a language.

x

Citations for Human TRAILR4/TNFRSF10D Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

18 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Distinct effects of TRAIL on the mitochondrial network in human cancer cells and normal cells: role of plasma membrane depolarization
    Authors: Yoshihiro Suzuki-Karasaki, Kyoko Fujiwara, Kosuke Saito, Miki Suzuki-Karasaki, Toyoko Ochiai, Masayoshi Soma
    Oncotarget
  2. Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps
    Authors: L Danish, D Imig, F Allgöwer, P Scheurich, N Pollak
    PLoS ONE, 2018-06-21;13(6):e0198203.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  3. Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes.
    Authors: Neumann S, Hasenauer J, Pollak N, Scheurich P
    J Biol Chem, 2014-04-24;289(23):16576-87.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  4. TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells.
    Authors: Tang X, Lu J, Tu H, Huang K, Fu R, Cao G, Huang M, Cheng L, Dai L, Zhang L
    Anticancer Res, 2014-02-01;34(2):729-34.
    Species: Rat
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  5. TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells.
    Cancer Gene Ther., 2012-07-06;19(9):652-8.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  6. Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL).
    Authors: Zauli G, Rimondi E, Celeghini C, Milani D, Secchiero P
    J. Cell. Physiol., 2010-02-01;222(2):357-64.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  7. Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients.
    Authors: Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Mullauer L, Quendler H, Kohrgruber N, Stingl G
    Blood, 2009-08-18;114(18):3854-63.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  8. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.
    Authors: Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, D'Aurizio F, di Iasio MG, Cesselli D, Bagnara GP, Zauli G
    Stem Cells, 2008-09-04;26(11):2955-63.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  9. Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms.
    Authors: Shankar S, Chen Q, Ganapathy S, Singh KP, Srivastava RK
    Mol. Cancer Ther., 2008-08-01;7(8):2328-38.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  10. Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
    Authors: Barbarotto E, Corallini F, Rimondi E, Fadda R, Mischiati C, Grill V, Vaccarezza M, Celeghini C
    J. Cell. Biochem., 2008-05-15;104(2):595-605.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  11. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
    Authors: Toscano F, Fajoui ZE, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, Scoazec JY, Micheau O, Abello J, Saurin JC
    Oncogene, 2008-03-17;27(30):4161-71.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  12. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
    Authors: Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B, Weller M
    Cell Death Differ., 2008-01-18;15(4):718-729.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  13. Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.
    Authors: Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM
    Mol. Cancer Ther., 2007-12-07;6(12):3219-28.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  14. Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells.
    Authors: Braun FK, Fecker LF, Schwarz C, Walden P, Assaf C, Durkop H, Sterry W, Eberle J
    J. Invest. Dermatol., 2007-05-10;127(10):2425-37.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  15. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma.
    Authors: Singh TR, Shankar S, Srivastava RK
    Oncogene, 2005-07-07;24(29):4609-23.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  16. Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of Glioblastoma
    Authors: Nivetha Krishna Moorthy, Oliver Seifert, Stephan Eisler, Sara Weirich, Roland E. Kontermann, Markus Rehm et al.
    Molecules
  17. Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy
    Authors: JD Yoo, SM Bae, J Seo, IS Jeon, SMP Vadevoo, SY Kim, IS Kim, B Lee, S Kim
    Sci Rep, 2020-11-17;10(1):19997.
  18. TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status
    Authors: Najib Ben Khaled, Katharina Hammer, Liangtao Ye, Ahmed Alnatsha, Sebastian A. Widholz, Ignazio Piseddu et al.
    Cancers (Basel)

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs
Loading...

Reviews for Human TRAILR4/TNFRSF10D Antibody

Average Rating: 4 (Based on 1 Review)

5 Star
0%
4 Star
100%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human TRAILR4/TNFRSF10D Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human TRAIL R4/TNFRSF10D Antibody
By Anonymous on 07/17/2018
Application: WB Sample Tested: SW480 human colorectal adenocarcinoma cell line Species: Human

SW480 cells were treated with 5-FU (1 mg/ml) for indicated time points. Total cell lysates were subjected to western blot. PVDF membrane were probed with 1mm/ml Human TRAIL R4 Antibody (MAB633). A specific band was detected for TRAIL R4 at approximately 45-55 kDa. This experiment was conducted under reducing conditions.